CSF proteins of inflammation, proteolysis and lipid transport define preclinical AD and progression to AD dementia in cognitively unimpaired individuals
Molecular Neurodegeneration, 2024
del Campo M., Quesada C., Vermunt L., Peeters C., Hok-A-Hin Y., Trieu C., Braber A., Verberk I., Visser P., Tijms B., van der Flier W., Teunissen C.
| Disease area | Application area | Sample type | Products |
|---|---|---|---|
Neurology | Patient Stratification | CSF | O Olink Target 96 |
Abstract
This preclinical AD CSF proteome study identified a panel of 12-CSF markers detecting amyloid positivity and clinical progression to AD with high accuracy; some of these CSF proteins related to immune function, neurotrophic processes, energy metabolism and endolysosomal functioning (e.g., ITGB2, CLEC5A, IGFBP-1, CST3) changed before amyloid positivity is established.